Esperion Therapeutics ESPR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 18.1%+31.8pp | 15%-2.7pp | -8.2%-13.8pp | -11.6%-13.4pp | -13.7%+1.4pp | |
| EBITDA margin | 18.1%+31.8pp | 15%-2.7pp | -8.2%-13.8pp | -11.5%-13.3pp | -13.7%+1.4pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.3× | 1×-0.2× | 0.9×-0.2× | 0.8×-0.2× | 0.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.5×+0.4× | 1.5×+0.2× | 1×-0.9× | 1.1×-0.8× | 1.2×-1.0× | |
| Quick ratio | 1.2×+0.4× | 1.2×+0.2× | 0.7×-0.7× | 0.8×-0.7× | 0.8×-1.0× | |
| Cash ratio | 0.5×+0.1× | 0.6×0.0× | 0.3×-0.6× | 0.3×-0.8× | 0.4×-1.0× | |
| Leverage | ||||||
| Debt-to-assets | 0.3×-0.1× | 0.3×-0.1× | 0.4×+0.4× | 0.4×+0.4× | 0.5×+0.4× | |
| Interest coverage | 0.9×+1.4× | 0.7×-0.3× | -0.3×-0.6× | -0.4×-0.5× | -0.5×0.0× | |
| Per Share | ||||||
| Book value per share | -$1.23+43.6% | -$1.45+30.0% | -$2.25-18.4% | -$2.19-20.4% | -$2.17-40.0% | |
| Valuation | ||||||
| Market capitalization | $811.73M+283% | $877.16M+102% | $534.3M+65.0% | $212.07M-49.6% | $284.9M-42.6% | |
| Enterprise value | $810.81M+233% | $864.28M+98.7% | $596.66M+222% | $276.51M+16.2% | $316.51M+14.6% | |
| Price / sales | 1.9×+1.1× | 2.2×+0.9× | 1.8×+0.7× | 0.8×-0.7× | 1.1×-1.1× | |
| EV / sales | 1.9×+1.0× | 2.1×+0.8× | 2×+1.3× | 1×+0.2× | 1.2×0.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Esperion Therapeutics's ratios come from?
- Every ratio is computed from Esperion Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
